Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 15/20 | 0.81 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.65 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.59 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704221 | 1.00 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3TAAR1 | |
| SCHEMBL6554405 | 1.00 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3TAAR1 | |
| SCHEMBL6565117 | 0.90 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878433 | 0.90 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877944 | 0.85 | GRIA4 (0.66) | GRIA4GRIA2GRIA1GRIA3TAAR1 | |
| SCHEMBL13255761 | 0.85 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.85 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877671 | 0.85 | GRIA4 (0.73) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878987 | 0.84 | GRIA4 (0.90) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6782561 | 0.83 | GRIA4 (0.68) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328125-B2 | Bivalent AMPA receptor positive allosteric modulators | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2013130501-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-06 | — | — | WO | disclosed |
| US-8097652-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097652-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097652-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY | 2010-01-14 | — | — | US | disclosed |
| EP-1294683-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002018329-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090055-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090056-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | GRIN1, GRIK2, GRIK1 | GRIA4 18/4885GRIA2 14/4885GRIA1 11/4885 |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | GRIK2, GABRE, GRIK4 | GRIA4 39/4885GRIA2 34/4885GRIA1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.